FY2030 Earnings Forecast for CADL Issued By HC Wainwright

Candel Therapeutics, Inc. (NASDAQ:CADL) – Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Candel Therapeutics in a research note issued to investors on Thursday, March 12th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of $2.91 per share for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.47) per share.

Several other equities analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, January 21st. Canaccord Genuity Group restated a “buy” rating and set a $25.00 price objective on shares of Candel Therapeutics in a research report on Friday. Stephens restated an “overweight” rating and set a $15.00 price objective on shares of Candel Therapeutics in a report on Monday, December 8th. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Citigroup dropped their price target on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Candel Therapeutics Trading Down 6.2%

CADL stock opened at $4.67 on Monday. Candel Therapeutics has a one year low of $4.25 and a one year high of $9.08. The stock has a market cap of $256.38 million, a price-to-earnings ratio of -6.58 and a beta of -0.90. The company has a fifty day moving average price of $5.59 and a two-hundred day moving average price of $5.42. The company has a debt-to-equity ratio of 0.91, a current ratio of 13.49 and a quick ratio of 13.49.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.30).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CADL. Acorn Capital Advisors LLC grew its stake in Candel Therapeutics by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 2,580,517 shares of the company’s stock valued at $13,057,000 after acquiring an additional 428,265 shares during the period. Vanguard Group Inc. grew its position in Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after purchasing an additional 219,563 shares during the period. Geode Capital Management LLC increased its stake in Candel Therapeutics by 31.5% during the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock valued at $4,575,000 after purchasing an additional 216,509 shares in the last quarter. Millennium Management LLC bought a new stake in Candel Therapeutics during the 3rd quarter valued at $697,000. Finally, State Street Corp raised its holdings in Candel Therapeutics by 15.0% during the fourth quarter. State Street Corp now owns 792,218 shares of the company’s stock worth $4,476,000 after buying an additional 103,452 shares during the last quarter. 13.93% of the stock is owned by institutional investors.

Insider Activity at Candel Therapeutics

In related news, Director Paul B. Manning acquired 550,458 shares of Candel Therapeutics stock in a transaction dated Monday, February 23rd. The stock was bought at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the transaction, the director directly owned 2,763,527 shares in the company, valued at $15,061,222.15. This represents a 24.87% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 16.60% of the stock is currently owned by company insiders.

Trending Headlines about Candel Therapeutics

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 price target (~435% upside vs. the current $4.67), supporting bullish sentiment and potential buying interest. Canaccord Genuity Buy Rating
• Positive Sentiment: Citigroup kept a “buy” rating while trimming its price target to $22.00 (still ~371% upside), which can lend confidence to momentum investors despite the lower PT. Citigroup Price Target Cut
• Positive Sentiment: Company update: Candel outlined progress advancing its lead cancer immunotherapy toward potential commercialization, announced planned Phase 3 trials and a regulatory filing timeline, and described actions to strengthen the balance sheet—news that supports long-term value drivers. Corporate Update & Balance Sheet
• Neutral Sentiment: Reported short-interest data in recent feeds shows zero shares and NaN changes (likely a reporting anomaly); this makes it hard to read short-seller pressure from public data today. (No reliable short-interest link available.)
• Negative Sentiment: Q4 earnings miss: Candel reported ($0.54) EPS vs. consensus ($0.24) loss, a material miss that likely triggered selling by near-term traders concerned about cash burn and near-term execution. Q4 Earnings Release
• Negative Sentiment: Debt covenant risk: An analyst note flagged restrictive covenants in the RTW purchase agreement that could limit financial flexibility and raise default risk—this increases investor concern about financing options and downside risk. RTW Covenant Risk Note

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.